Investment analysts at Leerink Swann started coverage on shares of Inflarx (NASDAQ:IFRX) in a research report issued on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.

Separately, J P Morgan Chase & Co initiated coverage on Inflarx in a report on Monday. They issued an “overweight” rating on the stock.

Inflarx (NASDAQ IFRX) opened at $20.88 on Monday. Inflarx has a 1-year low of $14.47 and a 1-year high of $22.48.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/04/inflarx-ifrx-now-covered-by-leerink-swann.html.

About Inflarx

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.

The Fly

Receive News & Ratings for Inflarx NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx NV and related companies with MarketBeat.com's FREE daily email newsletter.